Izithako ze-Liposomal NAD+: Ukukhula Kwemakethe, I-Bioavailability Innovation, kanye namathrendi okwakhiwa kwe-B2B

Kubaphathi bokuthengwa kwempahla kanye nabanikazi bomkhiqizo abahlola izithako zesizukulwane esilandelayo-zesikhathi eside, imakethe yezinsiza ze-NAD+ ibhekene noshintsho olubalulekile{2}} olungaqhutshwa ama-molecule amasha kuphela, kodwaliposomal NAD+ powderkanye nobuchwepheshe bokulethwa obuthuthukisiwe obubhekana nemikhawulo ye-bioavailability yokwenziwa komlomo okuvamile kwe-NAD+.

Le ndatshana igxile kakhulu emakethe yomkhiqizo oqediwe we-NAD+ yesithasiselo sokudla (ingxenye ye-booster), kuyilapho izibalo ze-ecosystem ebanzi zibhekiselwa kumongo. Imakethe ye-booster ye-NAD+ yomhlaba wonke yalinganiselwa ezigidini ezingama-593 zamaRandi ngonyaka ka-2025 futhi kulindeleke ukuthi ifinyelele ku-US $ 1.54 billion ngo-2032, ku-CAGR ye-14.8%. Kepha ngaphakathi kwalesi sigaba esikhulayo, ukulethwa kwe-liposomal kuvela njengokuhlukanisa okubalulekile, ukubumba kabusha ukuthi imikhiqizo yakheka kanjani, ibeka, futhi ihwebe ngemikhiqizo ye-NAD+ yemakethe ekhulayo yokuphila isikhathi eside.

 

 

 

• Imakethe ye-NAD+ yomhlaba wonke kulindeleke ukuthi ikhule isuka ku-$593 million ngo-2025 iye ku-$1.54 billion ngo-2032 ku-CAGR ye-14.8%.
• I-NAD+ precursor supplements yenze imali elinganiselwa ku-$346 million ekuthengisweni ngo-2025.
• Ucwaningo lwezokwelapha lwabantu lubike ukuthi ukwakheka kwe-liposomal NAD+ kungase kuthuthukise i-bioavailability uma kuqhathaniswa ne-NAD+ evamile, ngokunyuka okungu-1.52× kokutholakala kwe-bioavailability okubonwe ocwaningweni lomtholampilo.

Kubathengi be-B2B, imibandela yokuhlola ebalulekile ihlanganisa ukusebenza kahle kwe-encapsulation, ukusatshalaliswa kosayizi wezinhlayiyana, idatha yokuzinza, kanye{1}}nemibhalo ethile yokuhlaziya yenqwaba.

 

 

Ngaphambi kokuhlola ukuqagela kokukhula, kubalulekile ukucacisa izigaba zemakethe okubhekiselwe kuzo kukho konke lokhu kuhlaziywa.

I-NAD+ booster market-echazwa njengemikhiqizo eqediwe yezithako zokudla eklanyelwe ukuphakamisa amazinga e-NAD+{2}}yalinganiselwa ezigidini ezingu-US$593 ngo-2025 futhi kubikezelwa ukuthi izofinyelela ku-$1.54 billion ngo-2032, ku-CAGR engu-14.8%. Lokhu kumelela ingxenye efaneleke kakhulu yabathengi besithako se-B2B abakha imikhiqizo eyisithako eqediwe.

Uhlelo olubanzi lwemikhiqizo ye-NAD+-okuhlanganisa izindlela zokwelapha ze-IV, ama-reagents ocwaningo, izinhlelo zokusebenza zemithi, nemikhiqizo ehlobene{1}}inenani lamabhiliyoni angu-3.45 ngo-2024 futhi kulindeleke ukuthi ifinyelele ku-$12.18 billion ngo-2033, ikhula ku-CAGR ka-15.1%. Ngaphakathi kwalesi simiso semvelo esibanzi, imakethe yemikhiqizo yase-US NAD+ iyodwa ikhiqize imali eyizigidi ezingama- $ 622.2 emalini engenayo ngo-2024.

Izithako ze-NAD+ ezandulelayo(I-NMN ne-NR) yenze ukuthengiswa okulinganiselwa ku-$346 wezigidi ngo-2025, nokuqagela kwezigidi ezingu-447 zamaRandi ngo-2026 kanye namaRandi ayizigidi ezingu-557 ngo-2027. I-NMN kulindeleke ukuthi ibambe u-45% wesabelo semakethe esandulela se-NAD+ ngo-2025, eqhutshwa idatha yomtholampilo eqinile kanye nokuthenjwa kwabathengi.

Imakethe yemikhiqizo yase-Asia Pacific NAD+kulindeleke ukuthi ifinyelele ku-$8.18 billion ngo-2033, ikhule ku-CAGR ka-17%, okubonisa amathuba abalulekile okukhula kwesifunda.

Kusho ukuthini lokhu ekuthengeni:Ukukhula okuqhubekayo kuzo zonke izingxenye zemakethe ye-NAD+ kukhombisa ukwethenjwa kwezimboni ekwengezeni kwe-NAD+ njengesigaba. Ingxenye ye-premium, okuhlanganisa ukwakheka kwe-liposomal, ibamba ingxenye ekhulayo yalokhu kukhula.

 

 

Imakethe yezengezo ye-NAD+ ibhekene nokukhula okuqinile kuzo zonke izingxenye eziningi:

• INAD+ booster marketkulindeleke ukuthi ikhule ku-CAGR ka-14.8% ukusuka ngo-2025 kuya ku-2032.
• OkubanziImakethe yemikhiqizo ye-NAD+ikhule isuka ku- $5.59 billion ngo-2025 yaya ku- $6.48 billion ngo-2026 ku-CAGR ka-16.1%.
• Izithako ze-NAD+ ezandulelayokulindeleke ukuthi zikhule zisuka ku-$346 million ngo-2025 ziye ku-$557 million ngo-2027.
• Iimakethe ye-liposomal supplementskulindeleke ukuthi ifinyelele ezigidini ezingama-771.76 ngo-2025 futhi kulindeleke ukuthi ifinyelele ku- $ 1.52 billion ngo-2033, ikhule ku-CAGR ka-8.84%.
• Ukuphila isikhathi eside kubusa i-supplement innovationeYurophu, ngokufakwa kwe-NAD+ okuhlonzwe njengesu eliphezulu lika-2026.
• Imakethe yemikhiqizo yase-US NAD+ yenze imali engenayo eyizigidi ezingama- $622.2 ngonyaka ka-2024 futhi kulindeleke ukuthi ifinyelele ku-$1.77 billion ngo-2033. Imakethe yomhlaba wonke ye-NAD+ kanye nokuphila isikhathi eside kwe-nutraceutical supplement yalinganiselwa ku-$3.4 billion ngo-2025.

Kusho ukuthini lokhu ekuthengeni:Ukukhula okuqhubekayo kwamadijithi akabili{0}}kuzo zonke izingxenye zemakethe ye-NAD+ kubonisa ukukhula kokuqiniseka kwemboni ekusekelweni kwe-NAD+ njengesigaba. Ingxenye ye-premium, okuhlanganisa ukwakheka kwe-liposomal, ibamba ingxenye ekhulayo yalokhu kukhula.

 

 

Imakethe yezengezo ye-NAD+ ichazwa ngokwandayo ngobuchwepheshe bokulethwa kunokukhethwa kwezithako kuphela. Phakathi kwezixazululo ezivelayo, ukulethwa kwe-liposomal kuye kwaba enye yezindlela okuxoxwa ngazo kakhulu ekwakhiweni kwesithasiselo.

Inselele ye-bioavailability.Izithako ezivamile zomlomo ze-NAD+ zibhekana-nemikhawulo ebhaliwe ye-bioavailability. Iningi le-NAD+ yomlomo ayitholakali ngokuqondile futhi ivamise ukwenziwa i-metabolism ibe izandulela njenge-nicotinamide ngaphambi kokuthathwa kwesistimu. Lokhu ngokomlando kuvimbezele ukusebenza kwe-NAD+ yomlomo kanye nezimangalo zomkhiqizo ezinomkhawulo.

Indlela ye-liposomal.Amaphakheji we-Liposomal encapsulation NAD+ ngaphakathi kwe-phospholipid bilayers, enza ama-vesicles amancane angase avikele isithako esisebenzayo ekonakalisweni kwesisu futhi athuthukise amandla ayo okumuncwa. I-lipid bilayer ilingisa ulwelwesi lwamaseli omuntu, okungase kube lula ukutholwa kwamaselula okuthuthukisiwe.

Ubufakazi bomtholampilo womuntu.Ucwaningo lomtholampilo lwabantu lubonise ukwanda okungu-1.52× ku-NAD+ bioavailability ngokuhlelwa kwe-liposomal uma kuqhathaniswa ne-NAD evamile+. Ucwaningo olungahleliwe lwe-crossover olungahleliwe lubike ukuthi ukwengezwa komlomo kwansuku zonke nge-liposomal NAD+ ukulungiselela kwenyuse kakhulu amazinga e-intracellular NAD+ kubantu, ikakhulukazi kumthamo ongu-1,000 mg. Uhlolo lomtholampilo olungahleliwe,{9}}oluyimpumputhe, olunqamulayo luyaqhubeka manje uma kuqhathaniswa ne-pharmacokinetics ye-NAD yomdabu elawulwa ngomlomo kanye nokwakheka kwayo kwe-liposomal.

Ukuqinisekiswa kwemboni.Imakethe yomhlaba wonke ye-liposomal supplements kulindeleke ukuthi ifinyelele ezigidini ezingama-771.76 ngonyaka ka-2025 futhi kulindeleke ukuthi ifinyelele ku- $ 1.52 billion ngo-2033, ikhula ku-CAGR ka-8.84%. Lokhu kukhula kukhombisa ukwanda kokwamukelwa kokulethwa kwe-liposomal ezigabeni eziningi zokwengeza.

Kusho ukuthini lokhu ekuthengeni:Ukulethwa kwe-Liposomal kuba indlela esunguliwe yokuthuthukisa i-bioavailability. Ekwakhekeni kwe-NAD+, lapho ukuba khona kwe-bioavailability ngokomlando bekuwumkhawulo oyinhloko, ubuchwepheshe be-liposomal bumelela intuthuko engase isekele izimangalo zomkhiqizo othembeke kakhulu kanye nemiphumela yabathengi.

 

 

Ngale kokutholakala kwe-bioavailability, izinselelo ezimbalwa zokuqamba zithinta ngqo ukusebenza kwezentengiselwano kwemikhiqizo ye-liposomal NAD+. Amaqembu okuthenga kufanele ahlole abahlinzeki ngekhono labo lokubhekana nalezi zithiyo zobuchwepheshe.

Ukuzwela kwe-oxidation.I-NAD+ isengozini yokuwohloka kwe-oxidative ngesikhathi sokucubungula nokugcinwa. I-phospholipid bilayer ekwakhiweni kwe-liposomal inikeza ukuvikeleka okuthile, kodwa ukuzinza komthwali ngokwawo kuncike kukhwalithi ye-phospholipid kanye nezinhlelo ze-antioxidant. Abahlinzeki kufanele banikeze ICH-idatha ethobelayo yokuzinza ebonisa ukugcinwa kwamandla ngaphansi kwezimo{4}}zesikhathi sangempela sokulondoloza.

Ukulahlekelwa kwe-encapsulation ngesikhathi sokucubungula.Futha-ukomisa nokumiswa{1}}ukomisa kungonakalisa ubuqotho be-liposome uma amapharamitha enqubo engalawulwa ngokucophelela. Ukusebenza kahle kwe-encapsulation{3}}iphesenti le-NAD+ elivikelwe ngempumelelo ngaphakathi kwama-liposomes{5}}lihluka kakhulu phakathi kwabahlinzeki. Amaqembu okuthenga kufanele acele idatha ye-encapsulation esebenza kahle njengengxenye yokuhlola komhlinzeki.

Ukuwohloka kwe-phospholipid.Ama-phospholipids akha i-liposomal bilayer ngokwawo angenwa kalula yi-oxidation. Ukwakheka kwe-phospholipid (okugcwele uma kuqhathaniswa ne-unsaturated), umthombo (ubhekilanga, isoya, noma olwandle), kanye nezinhlelo ze-antioxidant (isb., i-alpha-tocopherol) konke kuthinta-ukuzinza kwesikhathi eside. Cela ulwazi ngekhwalithi ye-phospholipid nokuvikelwa kwe-antioxidant.

pH ukuzinza.Ukwakhiwa kwe-Liposomal kungathinteka yizimo ze-pH ezimbi kakhulu. Kuzicelo zesiphuzo, abakhi befomula kufanele baqinisekise ukuzinza kwe-liposome ngaphakathi kwebanga elithile le-pH lomkhiqizo oqediwe. Ukwakheka okuningi kwe-liposomal NAD+ kwenzelwe ukungathathi hlangothi ezindaweni ezine-acidic kancane.

Kusho ukuthini lokhu ekuthengeni:Abahlinzeki abanedatha yokuqina ebhaliwe, ukuqinisekiswa kokusebenza kahle kwe-encapsulation, nokulawulwa kwekhwalithi ye-phospholipid banikeza ukwethembeka okukhulu kokubunjwa. Ilebhu-Ukuzinza kwesikali akuhumushi ngaso sonke isikhathi emkhiqizweni wezohwebo{2}}ukuqinisekiswa kokuhlola kubalulekile ngaphambi kokukhiqiza{3}}okugcwele.

 

 

Kubathengi be-B2B, ikhwalithi ye-liposomal NAD+ powder inokwethenjelwa kuphela njengamandla obuchwepheshe bomphakeli nezinhlelo zekhwalithi. Imibandela yokuhlola eyinhloko ihlanganisa:

Amadokhumenti okuhlaziya ({0}}okungaxoxiswana ngawo):Iqoqo-Izitifiketi Eziqondile Zokuhlaziya (COA) ezifaka i-HPLC-okuqukethwe kwe-NAD+ okuqinisekisiwe, ukuhlaziywa kwe-heavy metal (ICP-}MS), idatha yokuphepha kwe-microbiological, nemibiko yensalela ye-solvent.

Usayizi we-particle nokusebenza kahle kwe-encapsulation:Abahlinzeki abathembekile bahlinzeka ngedatha ye-dynamic light scattering (DLS) ebonisa usayizi wezinhlayiyana osho incazelo kanye nenkomba ye-polydispersity. Idatha ye-encapsulation esebenza kahle ibalulekile ukuze kuqinisekiswe ubuqotho bokwakheka.

Idatha yokuzinza:I-ICH-izifundo zokuzinza ezithobelanayo (isikhathi esisheshayo nesangempela-) zibonisa ukuthi ingabe ama-liposome agcina ubuqotho bawo kanye nokusebenza kahle kwe-encapsulation esikhathini seshelufu esihlosiwe.

Ikhwalithi ye-Phospholipid nomthombo:Ukuzinza kwe-oxidative ye-liposomal carrier ngokwayo kubalulekile. Cela ulwazi lokwakheka kwe-phospholipid, umthombo, nohlelo lwe-antioxidant.

Izitifiketi nokuhambisana:Izitifiketi zokukhiqiza (cGMP, ISO 22000, FSSC 22000, HACCP) kanye{2}}nezitifiketi ezithize zemakethe (Kosher, Halal, Non-GMO Project Verified) zinikeza isiqinisekiso sezinhlelo zokuphatha ikhwalithi nokulawulwa kwenqubo.

Ukubonisa ngale kwe-Supply chain:Ukulandeleka kwempahla eluhlaza okubhalwe phansi, iqoqo-kuya{1}}inqwaba yedatha yokufana, nezinketho zendawo yokugcina impahla ukuze kusekelwe ukusatshalaliswa komhlaba wonke.

Umbono wokuthenga:Ngale kwentengo, izinqumo zokuthenga kufanele zibeke phambili ukubonisa ngale kokuhlaziya, ukungaguquguquki kokwakhiwa, ukuthobela imithetho, kanye{0}nokuthembeka kokunikezwa kwesikhathi eside ukuze kukhuliswe impumelelo yezentengiselwano.

 

 

 

Ukuguquguquka kwe-liposomal NAD+ powder kwenza ukwakheka kuzo zonke izigaba zomkhiqizo eziningi, ngasinye sinezidingo ezihlukile zobuchwepheshe namathuba okuma kwemakethe.

Izithasiselo ze-Premium yokuphila isikhathi eside.Umshayeli oyinhloko wokukhula we-liposomal NAD+ uhlala eyisigaba se-premium supplement. Ukuphila isikhathi eside kubusa ukusungulwa kwezinto ezintsha e-Europe, ngokufakwa kwe-NAD+ isu eliphezulu lika-2026. Amabhrendi aqondise abathengi abazimisele ukukhokhela isayensi{4}}ukusebenza okusekelwe kwesayensi baya ngokuya besebenzisa ukwakheka kwe-liposomal njengendlela yokuhlukanisa.

Iziphuzo ezisebenzayo.I-Liposomal NAD+ powder inikeza ukuhlakazeka okuthuthukisiwe uma kuqhathaniswa ne-NAD+ eluhlaza, okuvumela ukufakwa ezinhlelweni zesiphuzo kanye nokwakheka okuyimpuphu.

Ukuguga okunempilo nokusekelwa kwengqondo.Njengoba iminyaka yabantu emhlabeni wonke, isidingo sezithako ezisekela ukuguga okunempilo nokusebenza kwengqondo siyaqhubeka sikhula.

Ukwakhiwa kwenhlanganisela.Intshisekelo ekhulayo iyaboniswa ekuhlanganiseni izithuthukisi ze-NAD+ namanye ama-bioactive ejenti ukuze kukhiqizwe imiphumela ye-synergistic, okuhlanganisa ama-antioxidants afana ne-resveratrol, amavithamini B, kanye nemisoco yokusekela ye-mitochondrial efana ne-CoQ10.

Kusho ukuthini lokhu ekuthengeni:Imikhiqizo etshala imali ekwakhiweni kwe-liposomal NAD+ namuhla izibeka ekubambeni ukukhula kuzo zonke izigaba zezicelo eziningi nezimakethe zendawo. Abahlinzeki abanamakhono amisiwe okukhiqiza i-liposomal kanye nedatha yokuqina eqinisekisiwe banikeza amathuba okusebenzisana athembeke kakhulu.

 

 

Kubaphathi bokuthenga be-B2B nabathuthukisi bomkhiqizo, ikusasa lezithasiselo ze-NAD+ lilolongwa kabusha ngokushintsha okubalulekile: ukusuka ekukhethweni kwesithako kuya kubuchwepheshe bokulethwa. Imakethe yezengezo ye-NAD+ ikhula ngokushesha, nemakethe ye-NAD+ booster kulindeleke ukuthi ikhule ku-CAGR ka-14.8% ngo-2032. Ucwaningo lwezokwelapha lwabantu lubike ukuthi ukwakheka kwe-liposomal NAD+ kungase kuthuthukise ukutholakala kwe-bioavailability uma kuqhathaniswa ne-NAD+ evamile, ngokunyuka okungu-1.52× okubonwe ocwaningweni lomtholampilo. Isidingo sabathengi sesayensi{11}esisekelweyo, i-bioavailability{12}}imikhiqizo ethuthukisiwe iqhuba lokhu kukhula, futhi ukulethwa kwe-liposomal sekuvele njengobuchwepheshe obuyinhloko bokuthwebula leli thuba. Ngokubambisana nomphakeli obonisa izinto ngendlela yobuchwepheshe ohlinzeka ngamadokhumenti okuhlaziya aqinisekisiwe, idatha yokuzinza, nokuthobela imithetho, abakhiqizi bangabeka imikhiqizo yabo phambili emakethe yokuphila isikhathi eside ethuthukayo futhi bathwebule isidingo esikhulayo sokwakheka kwesayensi{14}}okusekelwe e-NAD+.

 

Izinyathelo Ezilandelayo Zokwakhiwa Kwakho

Amaklayenti amaningi aqala ngenqwaba yokuhlola (100-500 g) ukuze aqinisekise ukuhlakazeka, ukuzinza, nokusebenza kokwakheka ku-matrix yawo ethile ngaphambi kokukalela ekukhiqizeni ezentengiso. I-COA eqondene neqoqo, idatha yosayizi wezinhlayiyana, kanye nezifundo zokuzinza kuyatholakala ukuze kusekelwe inqubo yokuthuthukisa umkhiqizo wakho.

• [Cela amasampuli amaningi e-liposomal NAD+]- Hlola amamaki ethu e-liposomal NAD+ powder kumatrix wakho wokwenza.
• [Finyelela kumadokhumenti wezobuchwepheshe]- Buyekeza imibiko yokuhlola ye-HPLC, ukusatshalaliswa kosayizi wezinhlayiyana (i-DLS), ukuhlaziywa kwensimbi esindayo, nezifundo zokuzinza.
• [Xoxa ngokucaciswa ngokwezifiso]- Hlola ukugxila ngokwezifiso, izinketho ze-liposomal encapsulation, noma ukusekelwa kokwakhiwa.
• [Shejula ukubonisana kokwakhiwa]– Hlangana nethimba lethu le-R&D ukuze ubhekane ne-NAD+ bioavailability, ukuzinza, noma{1}}izinselelo ezithile zohlelo lokusebenza.

I-MOQ, isikhathi sokuhola, kanye nentengo yenqwaba kuyatholakala uma ucela. I-Wellgreen inikeza inqwaba-i-COA ethize, ukuhlaziya{2}}usayizi wezinhlayiyana, ukusekela ukwakheka, kanye nezinsizakalo ze-OEM/ODM kubakhiqizi bomhlaba wonke bezomsoco. Ukuze uthole ukwesekwa kobuchwepheshe, ukubonisana nokuklama, namakhotheshini ayinqwaba, xhumana nethimba lethu lonjiniyela kuliu@wellgreenxa.com.

 

Izithenjwa

1. Global Info Research. (2026). I-Global NAD+ Booster Market 2026 yiNkampani, Izifunda, Uhlobo kanye Nesicelo, Isibikezelo sango-2032.
2. Ucwaningo Nezimakethe. (2026). I-Nicotinamide Adenine Dinucleotide Market Report 2026.
3. Ijenali Yebhizinisi Lokudla Okunomsoco / SupplySide Journal. (2026). Izithasiselo ze-NAD+: Isayensi, izitayela zemakethe, imininingwane yokwakhiwa.
4. I-Grand View Research. (2026). I-Nicotinamide Adenine Dinucleotide Products Market Report 2033.
5. I-Grand View Research. (2026). I-Asia Pacific Nicotinamide Adenine Dinucleotide (NAD) Usayizi Wemakethe Yemikhiqizo & I-Outlook, 2033.
6. I-Grand View Research. (2026). I-United States Nicotinamide Adenine Dinucleotide (NAD) Usayizi Wemakethe Yemikhiqizo & I-Outlook, 2033.
7. I-MedPath. (2025). Ucwaningo Lomtholampilo Lokuqhathanisa Ukuthi I-NAD+ Ejwayelekile kanye Nokwakheka Kwe-Liposomal NAD+ Kuthathwa Kanjani Kubantu Abadala Abanempilo.
8. Ucwaningo Lwemakethe. (2026). Global Liposomal Supplements Industry Reports Analysis Report 2025, Isibikezelo kuya ku-2033.
9. Izithako Inethiwekhi / Mintel. (2026). I-Scouting out supplement innovation ngo-2026: Ukuphila isikhathi eside, impilo yabesifazane, nokuningi.